生物制剂时代糖皮质激素使用趋势:基于人群的分析
该研究利用加拿大曼尼托巴省IBD流行病学数据库,分析1997至2017年所有IBD患者的人均年累积糖皮质激素剂量。结果显示,克罗恩病(CD)年均暴露从419 mg/年降至169 mg/年(年降幅3.8%),溃疡性结肠炎(UC)从380降至240 mg/年(年降幅2.5%)。CD在2007年后下降加速(前1.9%/年,后5.7%/年),UC无此加速。
要点
- CD和UC患者糖皮质激素年均暴露在1997-2017年间均显著下降。
- CD患者2007年后糖皮质激素用量下降速率加快,UC无相应加速。
- 生物制剂的应用可能部分解释了CD中激素用量的加速下降。
核心结论
- 过去20年CD和UC患者的糖皮质激素使用均减少,CD在2007年后下降更明显。
研究设计与样本
- 基于曼尼托巴省IBD流行病学数据库的人群分析,纳入1997-2017年所有IBD患者,评估人均年累积激素剂量,采用Joinpoint分析趋势。
主要发现
- CD年均激素暴露从419 mg/年(1997)降至169 mg/年(2017),年降幅3.8%(95%CI 3.1-4.6)。
- UC年均激素暴露从380 mg/年降至240 mg/年,年降幅2.5%(95%CI 2.1-2.8)。
- CD在2007年前年降幅1.9%,2007年后年降幅5.7%;UC无相应加速。
临床怎么用
- 在生物制剂时代,临床应持续推动减少激素依赖,尤其CD患者可受益于生物制剂普及。
- 需进一步识别持续使用激素的驱动因素以优化IBD管理。
局限性
- 研究为观察性设计,无法确立因果关系;未报告影响持续激素使用的具体因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Corticosteroids are effective for inducing clinical remission in inflammatory bowel disease (IBD), but not for maintaining remission. Reducing corticosteroid use and dependence is an important treatment goal since their use is associated with adverse events. The extent to which the improvements in IBD therapy have led to less corticosteroid use in the modern era remains unclear. METHODS: We used the University of Manitoba Inflammatory Bowel Disease Epidemiologic Database to assess the cumulative annual dosing of corticosteroids on a per-patient basis for all persons with IBD in the province of Manitoba between 1997 and 2017. Joinpoint analysis was used to assess for trends in corticosteroid use and to look at variation in the trends over time. RESULTS: The mean annual exposure to corticosteroids decreased from 419 mg/yr (1997) to 169 mg/yr (2017) for Crohn's disease (CD) (annual decline: 3.8% per year, 95% confidence interval 3.1-4.6) and from 380 to 240 mg/yr in ulcerative colitis (UC) (annual decline: 2.5% per year, 95% confidence interval 2.1-2.8). In CD, there was an acceleration in the rate of decline after 2007 (pre-2007, 1.9% decline per year; after 2007, 5.7% per year); there was no corresponding acceleration in the rate of decline in UC. DISCUSSION: Corticosteroid use has decreased in both CD and UC over the past 2 decades, becoming more pronounced after 2007 in CD. Potential explanations include introduction and increasing penetrance of biologic therapy in CD and greater awareness of corticosteroid-related adverse events in IBD. Further work is required understand the drivers of persistent corticosteroid use in IBD and how this can be further reduced.
引用
- Targownik LE, Bernstein CN, Benchimol EI, et al. Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. Am J Gastroenterol. 2021. PMID: 33767103. doi:10.14309/ajg.0000000000001220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。